CV & Diabetes Market Forecast

Datamonitor
January 14, 2009
13 Pages - SKU: DFMN2151142
License type:
Table of Contents Related Reports
Introduction

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Reasons to Purchase
  • A detailed clinical and commercial assessment of all key cardiovascular and metabolic therapy areas.
  • An analysis of the portfolios of top 10 leading cardiovascular and metabolic companies.
  • Sales based sales forecasts for all key cardiovascular and metabolic active agents in the seven major markets to 2017.
Please note: this is delivered as a Zip file.


 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


Cardiovascular Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!